These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23024015)

  • 21. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis.
    Rudwaleit M; Claudepierre P; Kron M; Kary S; Wong R; Kupper H
    Arthritis Res Ther; 2010; 12(2):R43. PubMed ID: 20230622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial.
    Braun J; Baraliakos X; Hermann KG; Deodhar A; van der Heijde D; Inman R; Beutler A; Zhou Y; Xu S; Hsu B
    Ann Rheum Dis; 2014 Jun; 73(6):1107-13. PubMed ID: 23644549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study.
    Deodhar A; Reveille JD; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
    J Rheumatol; 2018 Mar; 45(3):341-348. PubMed ID: 29247154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial.
    Reveille JD; Deodhar A; Ince A; Chan EKH; Peterson S; Li N; Hsia EC; Kim L; Lo KH; Xu S; Harrison DD; Han C
    Value Health; 2020 Oct; 23(10):1281-1285. PubMed ID: 33032770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study.
    Smolen JS; Kay J; Doyle M; Landewé R; Matteson EL; Gaylis N; Wollenhaupt J; Murphy FT; Xu S; Zhou Y; Hsia EC
    Arthritis Res Ther; 2015 Jan; 17(1):14. PubMed ID: 25627338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study.
    Kay J; Matteson EL; Dasgupta B; Nash P; Durez P; Hall S; Hsia EC; Han J; Wagner C; Xu Z; Visvanathan S; Rahman MU
    Arthritis Rheum; 2008 Apr; 58(4):964-75. PubMed ID: 18383539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    van der Heijde D; Kivitz A; Schiff MH; Sieper J; Dijkmans BA; Braun J; Dougados M; Reveille JD; Wong RL; Kupper H; Davis JC;
    Arthritis Rheum; 2006 Jul; 54(7):2136-46. PubMed ID: 16802350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis.
    Inman RD; Maksymowych WP;
    J Rheumatol; 2010 Jun; 37(6):1203-10. PubMed ID: 20231198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study.
    Braun J; Baraliakos X; Hermann KG; van der Heijde D; Inman RD; Deodhar AA; Baratelle A; Xu S; Xu W; Hsu B
    Ann Rheum Dis; 2012 Jun; 71(6):878-84. PubMed ID: 22128083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Performance of ultrasound to monitor Achilles enthesitis in patients with ankylosing spondylitis during TNF-a antagonist therapy.
    Wang CH; Feng Y; Ren Z; Yang X; Jia JF; Rong MY; Li XY; Wu ZB
    Clin Rheumatol; 2015 Jun; 34(6):1073-8. PubMed ID: 25896532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial.
    Reveille JD; Hwang MC; Danve A; Kafka S; Peterson S; Lo KH; Kim L; Hsia EC; Chan EKH; Deodhar A
    Clin Rheumatol; 2021 Apr; 40(4):1331-1341. PubMed ID: 32926247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis.
    Rutgeerts P; Feagan BG; Marano CW; Padgett L; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Zhang H; Colombel JF; Reinisch W; Gibson PR; Sandborn WJ;
    Aliment Pharmacol Ther; 2015 Sep; 42(5):504-14. PubMed ID: 26119226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab.
    Wagner C; Visvanathan S; Braun J; van der Heijde D; Deodhar A; Hsu B; Mack M; Elashoff M; Inman RD
    Ann Rheum Dis; 2012 May; 71(5):674-80. PubMed ID: 22039165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies.
    Schett G; Baraliakos X; Van den Bosch F; Deodhar A; Østergaard M; Gupta AD; Mpofu S; Fox T; Winseck A; Porter B; Shete A; Gensler LS
    J Rheumatol; 2021 Aug; 48(8):1251-1258. PubMed ID: 33722947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
    Kremer J; Ritchlin C; Mendelsohn A; Baker D; Kim L; Xu Z; Han J; Taylor P
    Arthritis Rheum; 2010 Apr; 62(4):917-28. PubMed ID: 20131276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study.
    Deodhar A; Shiff NJ; Gong C; Chan EKH; Hsia EC; Lo KH; Akawung A; Kim L; Xu S; Reveille JD
    Rheumatol Ther; 2023 Aug; 10(4):983-999. PubMed ID: 37322274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial.
    Weinblatt ME; Bingham CO; Mendelsohn AM; Kim L; Mack M; Lu J; Baker D; Westhovens R
    Ann Rheum Dis; 2013 Mar; 72(3):381-9. PubMed ID: 22661646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
    Gordon KB; Duffin KC; Bissonnette R; Prinz JC; Wasfi Y; Li S; Shen YK; Szapary P; Randazzo B; Reich K
    N Engl J Med; 2015 Jul; 373(2):136-44. PubMed ID: 26154787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of a quantitative scoring of enthesitis in ankylosing spondylitis.
    Kaya A; Ozgocmen S; Kamanli A; Aydogan R; Yildirim A; Ardicoglu O
    J Clin Rheumatol; 2007 Dec; 13(6):303-6. PubMed ID: 18176136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.